|1.||Griffin, John H: 49 articles (11/2015 - 06/2002)|
|2.||Esmon, Charles T: 41 articles (12/2015 - 01/2002)|
|3.||Levi, Marcel: 34 articles (03/2015 - 06/2003)|
|4.||van der Poll, Tom: 31 articles (11/2015 - 06/2003)|
|5.||Fernández, José A: 24 articles (11/2015 - 06/2002)|
|6.||Zlokovic, Berislav V: 22 articles (01/2015 - 03/2003)|
|7.||Grinnell, Brian W: 21 articles (01/2015 - 12/2002)|
|8.||Rosing, Jan: 21 articles (08/2014 - 07/2002)|
|9.||Matthay, Michael A: 19 articles (07/2010 - 04/2003)|
|10.||Rosendaal, F R: 18 articles (06/2014 - 04/2000)|
09/01/2008 - "Since the initial Protein C Worldwide Evaluation in Severe Sepsis trial demonstrating efficacy of aPC therapy to reduce mortality of severe sepsis, follow-up studies have failed to resolve concerns about the low overall risk-to-benefit ratio of this therapy and suggest that it might only be effective in severely ill patients with the most aggravated forms of coagulopathy. "
05/01/2005 - "Anticoagulant therapy with activated protein C has been shown to improve survival in sepsis, the most common risk factor for the development of ALI/ARDS, and is now being studied in ALI/ARDS. "
10/14/2005 - "The studies, PROWESS and ADDRESS, enrolled a total of 4329 patients with risk ratio (RR) and 95% confidence interval (CI) data for effect on 28-day mortality relative to control treatment of 0.92 (0.83-1.02) suggesting that recombinant human activated protein C is not beneficial in severe sepsis. "
02/01/2003 - "The prospective, randomized, double-blind, placebo-controlled, Phase III, multicenter Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial suggested that drotrecogin alfa--recombinant human activated protein C--significantly improved 28-day mortality rates in acute sepsis (P = 0.005). "
01/01/2014 - "Activated protein C (aPC) plays a pivotal role in modulating a severe inflammatory response and is thought to be beneficial for patients with sepsis. "
|2.||Septic Shock (Toxic Shock Syndrome)
01/01/2009 - "Recombinant human activated Protein C (APC) is used as an adjunctive therapeutic treatment in septic shock. "
09/01/2014 - "Among patients with septic shock, do-not-resuscitate status acts as a strong confounder that may inform past discrepancies between observational and randomized studies of activated protein C. "
11/01/2012 - "Improvements in general quality of care such as speed of antimicrobial delivery leading to decreasing mortality of patients with septic shock may have contributed to the null results of the recently completed trial of recombinant human activated protein C in patients with septic shock."
11/01/2012 - "To evaluate the effectiveness of recombinant human activated protein C on mortality in a cohort of patients with septic shock and to explore possible reasons for inconsistent results in previous studies. "
11/01/2008 - "Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock."
|3.||Protein C Deficiency
04/01/1994 - "Identification of the spatial relationships of natural mutations in the protein C model is helpful for understanding manifestations of protein C deficiency and for identification of novel, functionally important molecular features and exosites."
08/01/2009 - "pneum and severe protein C deficiency at baseline, a significantly greater proportion of patients were no longer severely protein C deficient after 4 days of DrotAA therapy. "
02/01/2014 - "Subcutaneous protein C concentrate on its own or combined with an oral anticoagulant appears to be safe and effective as maintenance treatment of severe protein C deficiency. "
04/15/1999 - "In the present study, we screened for protein C amidolytic activity in patients admitted to the National Cardiovascular Center Hospital, and we identified among them 43 probands and 51 relatives with heterozygous protein C deficiency. "
05/01/1994 - "The familial study revealed that her sister and mother had both a decreased concentration and depressed activity of protein C, indicating that this is a case of congenital protein C deficiency. "
06/01/2003 - "The only molecule which has proven to be notably effective in reducing mortality is Activated Protein C interacting on coagulation/fibrinolysis, as well as on inflammation processes. "
12/01/2005 - "These results demonstrated the expression of components of the protein C pathway on gastric epithelial cells and that APC may play a critical role in the protection against gastric mucosal inflammation."
01/01/2015 - "In this study, we hypothesized that pharmacological doses of activated protein C can modulate allergic inflammation by inhibiting dendritic cells. "
04/01/2013 - "To study the role of the endothelial protein C receptor (EPCR) in the modulation of susceptibility to inflammation-induced vascular leak in vivo. "
01/01/2012 - "Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial."
11/01/2010 - "Although the evidence for the efficacy of activated protein C is not conclusive, it should be considered in patients that are at a high risk for death without any contraindications related to bleeding risk. "
07/01/2008 - "In patients with predisposition to bleeding, as in preterm infants, the inactivated form of protein C could serve as a safe therapeutic option. "
03/01/2015 - "Further study of the immunomodulatory effects of protein C may be warranted using mutant forms with decreased bleeding potential. "
01/01/2009 - "These data suggest that strict adherence to PROWESS trial exclusion criteria would further limit serious bleeding events associated with the use of recombinant human activated protein C."
09/01/2008 - "Activated protein C seems to increase the risk of (severe) bleeding, although the absolute risk is low in patients that were included in clinical trials. "
|1.||drotrecogin alfa activated (Xigris)
|6.||lipoprotein-associated coagulation inhibitor (TFPI)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Artificial Respiration (Mechanical Ventilation)
|5.||Transplantation (Transplant Recipients)